Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Forbius
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Sanofi Pasteur’s dengue vaccine candidate became the first of its type to enter phase III with announcement by the company of a new clinical study in Australia, part of global phase III clinical study programme for the prevention of dengue disease in children and adults.
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Formation Biologics, Inc.